Results 151 to 160 of about 13,805 (198)

Cysteine-selective [¹⁸⁸Re]Re(v) radiolabelling of a Nanobody® for targeted radionuclide therapy using a "chelate-then-click" approach. [PDF]

Chem Sci
Melis DR, Segers C, Wellens J, Van de Voorde M, Blacque O, Ooms M, Gasser G, Opsomer T.   +7 more
europepmc   +1 more source

A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR). [PDF]

BMC Cancer
Kryza D, Vinceneux A, Bidaux AS, Garin G, Tatu D, Cropet C, Badel JN, Perol D, Giraudet AL.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunomodulatory effects of targeted radionuclide therapy

2023
It is now clear that conventional radiation therapy can reinstate cell death immunogenicity. Recent preclinical data indicate that targeted radionuclide therapy that irradiate tumors at continuous low dose rate also can elicit immunostimulatory effects and represents a promising strategy to circumvent immune checkpoint inhibitor resistance.
Constanzo, J., Bouden, Y., Godry, L., Kotzki, P.-O., Deshayes, E., Pouget, J.-P.   +5 more
openaire   +2 more sources

Targeted Radionuclide Therapy of Melanoma

Seminars in Nuclear Medicine, 2016
An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic
Abdullah, Norain, Ekaterina, Dadachova
openaire   +2 more sources

Targeted Radionuclide Therapy - An Overview

Current Radiopharmaceuticals, 2013
Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional external beam therapy, RNT targets diseases at the cellular level rather than on a gross anatomical level.
Ashutosh, Dash, F F Russ, Knapp, M R A, Pillai   +2 more
openaire   +2 more sources

Targeted Radionuclide Therapy in Glioblastoma

ACS Applied Materials & Interfaces
Despite the development of various novel therapies, glioblastoma (GBM) remains a devastating disease, with a median survival of less than 15 months. Recently, targeted radionuclide therapy has shown significant progress in treating solid tumors, with the approval of Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer by the US Food and
Xiaobin Zhao, Vivianne Jakobsson, Yucen Tao, Tianzhi Zhao, Jingyan Wang, Pek-Lan Khong, Xiaoyuan Chen, Jingjing Zhang   +7 more
openaire   +2 more sources

Organs dosimetry in targeted radionuclide therapy

Radiation Physics and Chemistry, 2021
Abstract The objective of this study is to assess the patients' effective and organ dose during theranostic applications in Kuwait. In total, eighteen adults' patients were conducted nuclear medicine procedures with 177Lu Dotatate for theranostic purpose in Kuwait Cancer control center (KCCC), Kuwait.
Meshari Alnaaimi, Abdelmoneim Sulieman, Mohammed Alkhorayef, Hasan Salah, Musa Alduaij, Mosab Algaily, O. Alomair, Y. Alashban, H.I. Almohammad, David Bradley, C. Kappas   +10 more
openaire   +1 more source

Principles of Molecular Targeting for Radionuclide Therapy

2022
Molecular targeting requires assessing several factors that come into play such as the location of the target, the choice of radionuclide, the inertness of the bifunctional chelate and stability of the covalently bound halogens, matching the residence time in the tumor with the physical half-life of the radionuclide, the scale and scope of the disease,
Francesco Bartoli, William C. Eckelman, Marie Boyd, Robert J. Mairs, Paola A. Erba   +4 more
openaire   +3 more sources

Covalent targeted radioligands potentiate radionuclide therapy

Nature
Targeted radionuclide therapy, in which radiopharmaceuticals deliver potent radionuclides to tumours for localized irradiation, has addressed unmet clinical needs and improved outcomes for patients with cancer1-4. A therapeutic radiopharmaceutical must achieve both sustainable tumour targeting and fast clearance from healthy tissue, which remains a ...
Xi-Yang Cui, Zhu Li, Ziren Kong, Yu Liu, Hao Meng, Zihao Wen, Changlun Wang, Junyi Chen, Mengxin Xu, Yiyan Li, Jingyue Gao, Wenjia Zhu, Zhixin Hao, Li Huo, Shaoyan Liu, Zhi Yang, Zhibo Liu   +16 more
openaire   +2 more sources

Targeted radionuclide therapy for bone metastases

European Journal of Nuclear Medicine, 1993
Recent advances in targeted radiotherapy offer a new approach for the management of metastatic bone pain. This paper will review the scientific basis for radionuclide therapy and will examine the evidence for clinical efficacy. The therapeutic potential of targeted radiotherapy can only be appreciated by comparison with established treatments ...
openaire   +2 more sources